Pediatric Hepatitis A Treatment & Management
- Author: Nicholas John Bennett, MB, BCh, PhD; Chief Editor: Russell W Steele, MD more...
Approach Considerations
No specific therapy is available. The investigational antienteroviral drug pleconaril (Disoxaril; ViroPharma) has no activity against hepatitis A virus (HAV). Treatment is therefore supportive.
Hospitalization is indicated for patients with significant dehydration due to vomiting or those with fulminant hepatitis.
Consultation with a subspecialist is generally not required. Fulminant hepatitis warrants care by a pediatric gastroenterologist and, possibly, an intensive care specialist.
Go to Hepatitis A, Pediatric Hepatitis B, Pediatric Hepatitis C, and Viral Hepatitis complete information on these topics.
Supportive Care
Inpatient care is not needed for most patients with HAV infection. Some patients may require hospitalization for intravenous (IV) rehydration. Once emesis subsides and the patient can tolerate oral fluids, discharge is appropriate. In the rare case of fulminant hepatitis, transfer to a facility with pediatric subspecialty care is indicated.
Follow-up liver enzyme studies should be performed at monthly intervals until levels normalize. If elevations persist for longer than 3 months, complications or additional diagnoses should be considered.
Medications that have known liver toxicity should be avoided.
Postexposure Prophylaxis
Postexposure prophylaxis consists of the administration of HAV vaccine (preferred if the patient is >1 y and < 40 y) or immune globulin (IG) to contacts as soon as possible, but no later than 2 weeks after exposure. IG is given as an intramuscular injection of 0.02 mL/kg. It is 80-90% effective in preventing HAV infection by means of passive immunity.
HAV vaccine is currently licensed for use in children aged 12 months or older.[6, 7] One dose of vaccine leads to seroconversion in 88% of adult patients by 15 days and in 99% of adult patients by 1 month. When followed with a second dose 6 months later, the vaccine leads to 100% seroconversion.
Candidates for postexposure prophylaxis include household and sexual contacts of infected patients, contacts in childcare centers during outbreaks, and, if the patient is a food handler, others who work at the same establishment. Information regarding administration of hepatitis A vaccine after exposure (either alone or in addition to IG) is currently available.[8, 9, 10]
Immunization
Pre-exposure prophylaxis with HAV vaccine is recommended for persons aged 1 year or older who are traveling to countries where HAV infection is endemic. If the trip is shorter than 2 weeks, or if the patient is younger than 1 year, IG should be given. If the trip is longer than 3 months, a larger dose of IG (0.06 mL/kg) is needed for those who cannot receive the vaccine. Repeat dosing is recommended if the trip lasts longer than 5 months.
Others who should receive the vaccine include children aged 12-35 months, patients with chronic liver disease, homosexual or bisexual men, users of injectable illicit drugs, and those with a high occupational risk (those who work with nonhuman primates and HAV laboratory workers).[11]
Vaccination in areas of extremely high incidence of infection may only be cost-effective if prevaccination serology is obtained to target nonimmune individuals.[12]
The Advisory Committee on Immunization Practices (in the United States) has recommended universal immunization in all children older than 1 year (the lower limit of the approved age range) and catchup immunization in those who have not been vaccinated.[10]
Diet and Activity
No specific dietary changes are needed. In euvolemic patients with vomiting (but without dehydration that necessitates IV fluid therapy), appropriate intake of oral fluid is recommended, as with other viral illnesses.
Patients should not return to school or work for 1 week after the onset of illness. Hospitalized patients who use diapers or those who are incontinent should have contact isolation for 1 week after the onset of illness. Otherwise, activity can be resumed as tolerated.
Prevention
General prevention measures consist of good personal hygiene, handwashing, ingestion of safe drinking water, and proper sanitation. Prevention specific to hepatitis A infection includes the use of IG and HAV vaccine[13] (see Postexposure Prophylaxis and Immunization).
The use of contact precautions is recommended for hospitalized patients for 1 week after the onset of symptoms.
People with chronic liver conditions, such as infection with HBV or HCV, should also be vaccinated against hepatitis A virus.
Feinstone SM, Kapikian AZ, Purceli RH. Hepatitis A: detection by immune electron microscopy of a viruslike antigen associated with acute illness. Science. Dec 7 1973;182(116):1026-8. [Medline].
Todd EC, Greig JD, Bartleson CA, Michaels BS. Outbreaks where food workers have been implicated in the spread of foodborne disease. Part 4. Infective doses and pathogen carriage. J Food Prot. Nov 2008;71(11):2339-73. [Medline].
Wasley A, Grytdal S, Gallagher K. Surveillance for acute viral hepatitis--United States, 2006. MMWR Surveill Summ. Mar 21 2008;57(2):1-24. [Medline]. [Full Text].
Wasley A, Samandari T, Bell BP. Incidence of hepatitis A in the United States in the era of vaccination. JAMA. Jul 13 2005;294(2):194-201. [Medline].
Klevens RM, Miller JT, Iqbal K, Thomas A, Rizzo EM, Hanson H, et al. The evolving epidemiology of hepatitis a in the United States: incidence and molecular epidemiology from population-based surveillance, 2005-2007. Arch Intern Med. Nov 8 2010;170(20):1811-8. [Medline].
CDC. Notice to readers: FDA approval of Havrix (hepatitis A vaccine, inactivated) for persons aged 1-18 years. MMWR. December 9, 2005;54(48):1235-1236. [Full Text].
CDC. Notice to readers: FDA approval of VAQTA (hepatitis A vaccine, inactivated) for children aged >1 year. MMWR. October 14, 2005;54(40):1026. [Full Text].
Fiore AE, Wasley A, Bell BP. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. May 19 2006;55:1-23. [Medline]. [Full Text].
Victor JC, Monto AS, Surdina TY, Suleimenova SZ, Vaughan G, Nainan OV, et al. Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. N Engl J Med. Oct 25 2007;357(17):1685-94. [Medline]. [Full Text].
[Guideline] Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. Oct 19 2007;56(41):1080-4. [Medline].
AAP. Hepatitis A vaccine recommendations. Pediatrics. Jul 2007;120(1):189-99. [Medline].
Ahmed M, Munshi SU, Nessa A, Ullah MS, Tabassum S, Islam MN. High prevalence of hepatitis A virus antibody among Bangladeshi children and young adults warrants pre-immunization screening of antibody in HAV vaccination strategy. Indian J Med Microbiol. Jan-Mar 2009;27(1):48-50. [Medline].
Hammitt LL, Bulkow L, Hennessy TW, Zanis C, Snowball M, Williams JL, et al. Persistence of antibody to hepatitis A virus 10 years after vaccination among children and adults. J Infect Dis. Dec 15 2008;198(12):1776-82. [Medline].

